Keith R. Walley
Corporate Officer/Principal at University of British Columbia
Keith R. Walley active positions
| Companies | Position | Start | End |
|---|---|---|---|
| University of British Columbia | Corporate Officer/Principal | - | - |
Career history of Keith R. Walley
Former positions of Keith R. Walley
| Companies | Position | Start | End |
|---|---|---|---|
Cyon Therapeutics, Inc.
 Cyon Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Cyon Therapuetics, Inc. operates as a clinical phase biotechnology company. It provides anti-PCSK9 which develops the treatment for sepsis-severe. The company was founded by James Russell, Keith Walley and John Boyd in May 2014 and is headquartered in Vancouver, Canada. | Founder | 2014-04-30 | 2014-05-01 |
Sirius Genomics, Inc.
 Sirius Genomics, Inc. Pharmaceuticals: MajorHealth Technology Sirius Genomics, Inc. develops DNA-based diagnostic and pharmacogenetic products. Its product is Sepsis. It also develops companion diagnostics, that are closely tied to therapeutic decisions, leading to better patient outcomes through personalized medicine. Sirius generates value by improving the safety and effectiveness of pharmaceutical compounds. The company correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable CDx products. Sirius Genomics was founded by James A. Russell and Keith Walley in 2001 and is headquartered in Vancouver, Canada. | Director/Board Member | 2000-12-31 | - |
| Founder | 2000-12-31 | - |
Training of Keith R. Walley
| University of Manitoba | Doctorate Degree |
Statistics
International
| Canada | 5 |
Operational
| Founder | 2 |
| Director/Board Member | 1 |
| Doctorate Degree | 1 |
Sectoral
| Consumer Services | 3 |
| Health Technology | 2 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
Sirius Genomics, Inc.
Sirius Genomics, Inc. Pharmaceuticals: MajorHealth Technology Sirius Genomics, Inc. develops DNA-based diagnostic and pharmacogenetic products. Its product is Sepsis. It also develops companion diagnostics, that are closely tied to therapeutic decisions, leading to better patient outcomes through personalized medicine. Sirius generates value by improving the safety and effectiveness of pharmaceutical compounds. The company correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable CDx products. Sirius Genomics was founded by James A. Russell and Keith Walley in 2001 and is headquartered in Vancouver, Canada. | Health Technology |
Cyon Therapeutics, Inc.
Cyon Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Cyon Therapuetics, Inc. operates as a clinical phase biotechnology company. It provides anti-PCSK9 which develops the treatment for sepsis-severe. The company was founded by James Russell, Keith Walley and John Boyd in May 2014 and is headquartered in Vancouver, Canada. | Commercial Services |
- Stock Market
- Insiders
- Keith R. Walley
- Experience